RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 CONFIRM Trial Final Analysis of Overall Survival: Fulvestrant 500 versus 250 mg
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 12
IS 20
SP 12
OP 13
DO 10.1177/155989771220009
UL http://mdc.sagepub.com/content/12/20/12.abstract
AB The Comparison of Fulvestrant 250 mg and 500 mg in Postmenopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy [CONFIRM] trial compared treatment with 2 doses of fulvestrant (250 vs 500 mg) in postmenopausal women with locally advanced or metastatic estrogen receptor (ER)-positive breast cancer that had recurred or progressed after endocrine therapy. The primary analysis showed that progression-free survival was significantly increased with fulvestrant 500 versus 250 mg [Di Leo A et al. J Clin Oncol 2010]. This article discusses the final analysis of overall survival.